The lineage plasticity characteristic of KMT2A-rearranged ALL is important in the context of immunotherapy, as this may facilitate loss of expression of CD19 and escape from CD19 Chimeric antigen receptor T cell (CAR-T) therapy [65]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.